{
    "root": "3533c2ca-1653-8676-e063-6294a90a6a59",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Sevelamer Hydrochloride",
    "value": "20250515",
    "ingredients": [
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "DIACETYLATED MONOGLYCERIDES",
            "code": "5Z17386USF"
        },
        {
            "name": "STEARIC ACID",
            "code": "4ELV7Z65AP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37527"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16134"
        },
        {
            "name": "SEVELAMER HYDROCHLORIDE",
            "code": "GLS2PGI8QG",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32127"
        }
    ],
    "indications": {
        "text": "sevelamer hydrochloride tablets indicated control serum phosphorus patients chronic kidney disease ( ckd ) dialysis . safety efficacy sevelamer hydrochloride tablets ckd patients dialysis studied .",
        "doid_entities": [
            {
                "text": "chronic kidney disease (DOID:784)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_784"
            },
            {
                "text": "kidney disease (DOID:557)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_557"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "chronic kidney disease",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_133"
            }
        ]
    },
    "contraindications": {
        "text": "patients taking phosphate binder.the recommended starting dose sevelamer hydrochloride tablets 800 mg 1600 mg , administered one two 800 mg sevelamer hydrochloride tablets two four 400 mg sevelamer hydrochloride tablets , meals based serum phosphorus level . table 1 provides recommended starting doses sevelamer hydrochloride tablets patients taking phosphate binder . table 1 : starting dose dialysis patients taking phosphate binder serum phosphorus sevelamer hydrochloride tablets 800 mg sevelamer hydrochloride tablets 400 mg greater 5.5 less 7.5 mg/dl 1 tablet three times daily meals 2 tablets three times daily meals greater equal 7.5 less 9 mg/dl 2 tablets three times daily meals 3 tablets three times daily meals greater equal 9 mg/dl 2 tablets three times daily meals 4 tablets three times daily meals patients switching calcium acetate.in study 84 ckd patients hemodialysis , similar reduction serum phosphorus seen equivalent doses ( approximately mg mg ) sevelamer hydrochloride tablets calcium acetate . table 2 gives recommended starting doses sevelamer hydrochloride tablets based patient \u2019 current calcium acetate dose . table 2 : starting dose dialysis patients switching calcium acetate sevelamer hydrochloride tablets calcium acetate 667 mg ( tablets per meal ) sevelamer hydrochloride tablets 800 mg ( tablets per meal ) sevelamer hydrochloride tablets 400 mg ( tablets per meal ) 1 tablet 1 tablet 2 tablets 2 tablets 2 tablets 3 tablets 3 tablets 3 tablets 5 tablets dose titration patients taking sevelamer hydrochloride tablets.adjust based serum phosphorus concentration goal lowering serum phosphorus 5.5 mg/dl less . increase decrease one tablet per meal two-week intervals necessary . table 3 gives dose titration guideline . average dose phase 3 trial designed lower serum phosphorus 5 mg/dl less approximately three sevelamer hydrochloride 800 mg tablets per meal . maximum average daily sevelamer hydrochloride tablets dose studied 13 g. table 3 : dose titration guideline serum phosphorus sevelamer hydrochloride tablets dose greater 5.5 mg/dl increase 1 tablet per meal 2-week intervals 3.5 5.5 mg/dl maintain current dose less 3.5 mg/dl decrease 1 tablet per meal",
        "doid_entities": [
            {
                "text": "ckd (DOID:784)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_784"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "800 mg : white white colored , oval shaped , film-coated tablets imprinted `` l 26 `` one side plain side . ndc : 72162-2501-2 : 180 tablets bottle storage : store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) sevelamer hydrochloride tablets expiration date bottle . [ usp controlled room temperature ] . protect moisture . repackaged/relabeled : bryant ranch prepack , inc. burbank , ca 91504",
    "adverseReactions": "sevelamer hydrochloride tablets contraindicated patients bowel obstruction . sevelamer hydrochloride tablets contraindicated patients known hypersensitivity sevelamer hydrochloride excipients .",
    "indications_original": "Sevelamer hydrochloride tablets are indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis. The safety and efficacy of sevelamer hydrochloride tablets in CKD patients who are not on dialysis have not been studied.",
    "contraindications_original": "Patients Not Taking a Phosphate Binder.The recommended starting dose of sevelamer hydrochloride tablets is 800 mg to 1600 mg, which can be administered as one or two 800 mg sevelamer hydrochloride tablets or two to four 400 mg sevelamer hydrochloride tablets, with meals based on serum phosphorus level. Table 1 provides recommended starting doses of sevelamer hydrochloride tablets for patients not taking a phosphate binder.\n\n \n                  \n                  \n                     Table 1: Starting Dose for Dialysis Patients Not Taking a Phosphate Binder\n                  \n                  \n                  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n                  \n                     \n                     \n                     \n                     \n                        \n                           \u00a0\n    \n     Serum Phosphorus\n                                \u00a0\n   \n    \n                           \u00a0\n    \n     Sevelamer Hydrochloride Tablets 800 mg\n                                \u00a0\n   \n    \n                           \u00a0\n    \n     Sevelamer Hydrochloride Tablets 400 mg\n                                \u00a0\n   \n    \n                        \n                     \n                     \n                        \n                           \u00a0Greater than 5.5 and less than 7.5 mg/dL \n       \u00a0\n    \n                           \u00a01 tablet three times daily with meals \n       \u00a0\n    \n                           \u00a02 tablets three times daily with meals \n       \u00a0\n    \n                        \n                        \n                           \u00a0Greater than or equal \n       \u00a0to 7.5 and less than 9 mg/dL \n       \u00a0\n    \n                           \u00a02 tablets three times daily with meals \n       \u00a0\n    \n                           \u00a03 tablets three times daily with meals \n       \u00a0\n    \n                        \n                        \n                           \u00a0Greater than or equal \n       \u00a0to 9 mg/dL \n       \u00a0\n    \n                           \u00a02 tablets three times daily with meals \n       \u00a0\n    \n                           \u00a04 tablets three times daily with meals \n       \u00a0\n    \n                        \n                     \n                  \n                  \n                     \u00a0\n                  \n                  \n                     Patients Switching from Calcium Acetate.In a study in 84 CKD patients on hemodialysis, a similar reduction in serum phosphorus was seen with equivalent doses (approximately mg for mg) of sevelamer hydrochloride tablets and calcium acetate. Table 2 gives recommended starting doses of sevelamer hydrochloride tablets based on a patient\u2019s current calcium acetate dose.\n\n \n                  \n                  \n                     Table 2: Starting Dose for Dialysis Patients Switching From Calcium Acetate to Sevelamer Hydrochloride Tablets\n                  \n                  \n                  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n                  \n                     \n                     \n                     \n                     \n                        \n                           \u00a0\n    \n     Calcium Acetate 667 mg \n        (Tablets per meal)\n     \n                                \u00a0\n   \n    \n                           \u00a0\n    \n     Sevelamer Hydrochloride Tablets 800 mg \n        (Tablets per meal)\n     \n                                \u00a0\n   \n    \n                           \u00a0\n    \n     Sevelamer Hydrochloride Tablets 400 mg \n        (Tablets per meal)\n     \n                                \u00a0\n   \n    \n                        \n                     \n                     \n                        \n                           \u00a01 tablet \n       \u00a0\n    \n                           \u00a01 tablet \n       \u00a0\n    \n                           \u00a02 tablets \n       \u00a0\n    \n                        \n                        \n                           \u00a02 tablets \n       \u00a0\n    \n                           \u00a02 tablets \n       \u00a0\n    \n                           \u00a03 tablets \n       \u00a0\n    \n                        \n                        \n                           \u00a03 tablets \n       \u00a0\n    \n                           \u00a03 tablets \n       \u00a0\n    \n                           \u00a05 tablets \n       \u00a0\n    \n                        \n                     \n                  \n                  \n                     \u00a0\n                  \n                  \n                     Dose Titration for All Patients Taking Sevelamer Hydrochloride Tablets.Adjust dosage based on the serum phosphorus concentration with a goal of lowering serum phosphorus to 5.5 mg/dL or less. Increase or decrease by one tablet per meal at two-week intervals as necessary. Table 3 gives a dose titration guideline. The average dose in a Phase 3 trial designed to lower serum phosphorus to 5 mg/dL or less was approximately three sevelamer hydrochloride 800 mg tablets per meal. The maximum average daily sevelamer hydrochloride tablets dose studied was 13 g.\n\n \n                  \n                  \n                     Table 3: Dose Titration Guideline\n                  \n                  \n                  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n                  \n                     \n                     \n                     \n                        \n                           \u00a0\n    \n     Serum Phosphorus\n                                \u00a0\n   \n    \n                           \u00a0\n    \n     Sevelamer Hydrochloride Tablets Dose\n                                \u00a0\n   \n    \n                        \n                     \n                     \n                        \n                           \u00a0Greater than 5.5 mg/dL \n       \u00a0\n    \n                           \u00a0Increase 1 tablet per meal at 2-week intervals \n       \u00a0\n    \n                        \n                        \n                           \u00a03.5 to 5.5 mg/dL \n       \u00a0\n    \n                           \u00a0Maintain current dose \n       \u00a0\n    \n                        \n                        \n                           \u00a0Less than 3.5 mg/dL \n       \u00a0\n    \n                           \u00a0Decrease 1 tablet per meal",
    "warningsAndPrecautions_original": "800 mg: White to off white colored, oval shaped, film-coated tablets imprinted with \"L 26\" on one side and plain on other side.\n                  \n                  NDC: 72162-2501-2: 180 Tablets in a BOTTLE\n                  \n                  Storage: Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F)\n                  Do not use sevelamer hydrochloride tablets after the expiration date on the bottle.\n  \n[See USP controlled room temperature].\n \n                  Protect from moisture.\n                  \n                  Repackaged/Relabeled by:\n  \nBryant Ranch Prepack, Inc.\n  \nBurbank, CA 91504",
    "adverseReactions_original": "Sevelamer hydrochloride tablets are contraindicated in patients with bowel obstruction.\n                  Sevelamer hydrochloride tablets are contraindicated in patients with known hypersensitivity to sevelamer hydrochloride or to any of the excipients.",
    "drug": [
        {
            "name": "Sevelamer Hydrochloride",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32127"
        }
    ]
}